Bridger Management LLC Acquires 946,086 Shares of Atara Biotherapeutics Inc (ATRA)

Bridger Management LLC grew its holdings in Atara Biotherapeutics Inc (NASDAQ:ATRA) by 57.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 2,598,599 shares of the biotechnology company’s stock after acquiring an additional 946,086 shares during the quarter. Atara Biotherapeutics accounts for approximately 3.1% of Bridger Management LLC’s investment portfolio, making the stock its 16th biggest position. Bridger Management LLC owned about 0.07% of Atara Biotherapeutics worth $47,035,000 at the end of the most recent quarter.

Other institutional investors have also made changes to their positions in the company. SG Americas Securities LLC bought a new stake in shares of Atara Biotherapeutics in the third quarter valued at about $142,000. Voya Investment Management LLC boosted its position in shares of Atara Biotherapeutics by 16.2% in the second quarter. Voya Investment Management LLC now owns 11,813 shares of the biotechnology company’s stock valued at $165,000 after acquiring an additional 1,651 shares during the period. Russell Investments Group Ltd. bought a new stake in shares of Atara Biotherapeutics in the third quarter valued at about $170,000. The Manufacturers Life Insurance Company boosted its position in shares of Atara Biotherapeutics by 7.2% in the second quarter. The Manufacturers Life Insurance Company now owns 20,377 shares of the biotechnology company’s stock valued at $285,000 after acquiring an additional 1,369 shares during the period. Finally, Dimensional Fund Advisors LP boosted its position in shares of Atara Biotherapeutics by 2.9% in the second quarter. Dimensional Fund Advisors LP now owns 21,718 shares of the biotechnology company’s stock valued at $304,000 after acquiring an additional 610 shares during the period. 76.88% of the stock is owned by institutional investors.

How to Become a New Pot Stock Millionaire

In related news, CEO Isaac E. Ciechanover sold 48,500 shares of the company’s stock in a transaction dated Wednesday, January 24th. The shares were sold at an average price of $34.58, for a total transaction of $1,677,130.00. Following the completion of the sale, the chief executive officer now owns 348,978 shares of the company’s stock, valued at $12,067,659.24. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Isaac E. Ciechanover sold 22,200 shares of the company’s stock in a transaction dated Friday, December 29th. The stock was sold at an average price of $18.29, for a total transaction of $406,038.00. The disclosure for this sale can be found here. Insiders have sold 347,197 shares of company stock valued at $10,700,913 in the last ninety days. 16.20% of the stock is currently owned by company insiders.

Shares of Atara Biotherapeutics Inc (NASDAQ ATRA) opened at $44.15 on Monday. Atara Biotherapeutics Inc has a 52-week low of $11.80 and a 52-week high of $49.90.

ATRA has been the subject of a number of recent research reports. BidaskClub raised shares of Atara Biotherapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, January 11th. Canaccord Genuity reissued a “buy” rating on shares of Atara Biotherapeutics in a research report on Friday, December 29th. Jefferies Group boosted their target price on shares of Atara Biotherapeutics from $30.00 to $46.00 and gave the company a “buy” rating in a research report on Monday, March 5th. Zacks Investment Research raised shares of Atara Biotherapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, February 15th. Finally, ValuEngine raised shares of Atara Biotherapeutics from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. One analyst has rated the stock with a sell rating, four have given a hold rating and five have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $33.80.

TRADEMARK VIOLATION NOTICE: “Bridger Management LLC Acquires 946,086 Shares of Atara Biotherapeutics Inc (ATRA)” was first posted by Markets Daily and is owned by of Markets Daily. If you are reading this report on another site, it was stolen and reposted in violation of US & international copyright law. The legal version of this report can be accessed at https://www.themarketsdaily.com/2018/03/12/bridger-management-llc-acquires-946086-shares-of-atara-biotherapeutics-inc-atra.html.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.

Want to see what other hedge funds are holding ATRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Atara Biotherapeutics Inc (NASDAQ:ATRA).

Institutional Ownership by Quarter for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply